Denmark-based Bavarian Nordic has signed an agreement to acquire rabies and tick-borne encephalitis (TBE) vaccines from GlaxoSmithKline in a deal valued at around €796m ($888m).
Swiss pharmaceutical company Acino has agreed to acquire Takeda’s select over-the-counter (OTC) and prescription pharmaceutical assets in multiple Near East, Middle East and Africa (NEMEA) countries for a total value of more than $200m.
French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.
US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.
German pharma giant Bayer has agreed to offload its animal health unit to Elanco Animal Health for $7.6bn (£6.27bn) in a stock-cum-cash deal, in a move to focus on its life sciences business.
Pfizer announced the closing of its joint venture (JV) with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.
Pfizer has agreed to merge its off-patent branded and generic established medicines business Upjohn with Mylan to establish a new global pharmaceutical company.
Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.
Sandoz has announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment.
Swiss drugmaker Novartis has completed the acquisition of dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn (£2.6bn) upfront in cash.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.